Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Value-Based Cancer Care

- PMLiVE

FDA approves Bavarian Nordic’s smallpox and monkeypox vaccine

First live non-replicating vaccine for both diseases

- PMLiVE

Genital herpes vaccine candidate heads for human studies

Follows decades of failed R&D into sexually-transmitted infection

- PMLiVE

Labour Party takes aim at pharma, calls attention to Orkambi row

Proposal to introduce compulsory licensing faces industry criticism

Novartis building

Novartis points finger at AveXis execs in Zolgensma data scandal

Announces remediation plan including whistleblower scheme

Why Marry?

Just like people, firms marry for many different reasons

- PMLiVE

Women living with cancer feel stigmatized, says new report

Highlights need for increased education, awareness and support

- PMLiVE

Lucid Group start the countdown to its big move

One month to go until Lucid Group moves into their new London Headquarters

Lucid Group Communications Limited

HCP insights_ What about me?

Four Health Wins at the PM Society Digital Awards

A very successful evening at the PM Society Digital Awards last night for the Four Health team! We brought home three Golds, one Silver and one Bronze making us the...

Four Agency Worldwide

- PMLiVE

Abeona Therapeutics’ rare disease phase 3 trial halted due to FDA concerns

Issues over transport stability must be resolved, says regulator

Richard Oakham

Growth and innovation in design and digital tech at Porterhouse

Porterhouse Medical Group is delighted to announce that Richard Oakham has been promoted to the role of Creative Director.Since joining our agency, Richard has made a very positive impact to...

Porterhouse Medical Group

- PMLiVE

Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

Will likely face competition soon from rival Rozlytrek

EU flag

GW Pharma’s Epidyolex gets EU approval for severe epilepsy

Company is confident it can overturn preliminary 'no' from NICE

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links